Emerging Alzheimer's disease treatment paradigms: A late‐stage clinical trial review
Abstract INTRODUCTION Without disease‐modifying interventions, Medicare and Medicaid spending on Alzheimer's disease (AD) management is expected to reach 637 billion USD annually by 2050. The recent advent of promising AD therapies after decades of a near‐total failure rate in clinical trials s...
Saved in:
| Main Authors: | Jakub P. Hlávka, Andrew T. Kinoshita, Divya Jeyasingh, Cheng Huang, Leila Mirsafian, Mireille Jacobson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In search of Alzheimer’s disease treatment methods: trends of clinical trials
by: G. Pakulaitė, et al.
Published: (2018-03-01) -
Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
by: Luke E. Stoeckel, et al.
Published: (2025-01-01) -
The “added value” of enrolling hematological patients in clinical trials: a single-center experience
by: Stefano Loiacono, et al.
Published: (2025-07-01) -
Predictors of knowledge level and awareness towards the principles and methodology evaluation of pharmacoeconomics in Saudi Arabia
by: Dhafer Mahdi Alshayban
Published: (2025-12-01) -
Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
by: Jeffrey C. Yu, et al.
Published: (2022-01-01)